Evidence map›Paper›PMID 39850411›Full record

ReviewHeliyon2025

Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review.

Charlotte Jacob, Marleen Tollenaere, Hanane Kachar, Marie-Claude Potier, Peter Paul De Deyn, Debby Van Dam

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Charlotte JacobLaboratory of Neurochemistry and Behaviour, Experimental Neurobiology Unit, University of Antwerp, Belgium.
Marleen TollenaereLaboratory of Neurochemistry and Behaviour, Experimental Neurobiology Unit, University of Antwerp, Belgium.
Hanane KacharLaboratory of Neurochemistry and Behaviour, Experimental Neurobiology Unit, University of Antwerp, Belgium.
Marie-Claude PotierInstitut du Cerveau, Pitié-Salpêtrière Hospital, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Paris, France.
Peter Paul De DeynLaboratory of Neurochemistry and Behaviour, Experimental Neurobiology Unit, University of Antwerp, Belgium.
Debby Van DamLaboratory of Neurochemistry and Behaviour, Experimental Neurobiology Unit, University of Antwerp, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

People with Down Syndrome (DS) are at high risk of developing Alzheimer's disease dementia (AD) and cerebral amyloid angiopathy, which is a critical factor contributing to dementia in sporadic AD. Predicting and monitoring the decline and onset of dementia is a diagnostic challenge and of essence in daily care and support for people with DS. In this literature scoping review, we first summarize the different blood-based biomarkers for AD in DS. Next, we describe urine-based biomarkers for AD in DS and finally, we explore various blood-based biomarkers in the general AD population. Apart from the classic amyloid beta and Tau biomarkers, we also discuss more out-of-the-box biomarkers such as neurofilament light chain, Dual-specificity tyrosine-regulated kinase 1A, and monoaminergic biomarkers. These potential biomarkers could be a valuable addition to the established panel of fluid biomarkers.

Indexed as

BloodCerebral amyloid angiopathyDYRK1AMonoaminergic biomarkersNeurofilament light chainUrine

Identifiers

PMID39850411
PMCPMC11755057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.